Imagion Biosystems (ASX: IBX) announced the U.S. Food and Drug Administration completed its review of the company's investigational new drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE